Professor David Church, Cancer Research UK Senior Cancer Research Fellow (Nuffield Department of Medicine) and OUCAGS CL NIHR alumnus, is the lead investigator for Phase 1 of the INTERCEPT-Lynch trial.
The trial is part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention. It has received authorisation from the Medicines and Healthcare products Regulatory Agency and is expected to begin recruiting participants this summer.